For a general practitioner in Oslo or a physiotherapist in Copenhagen, the final patient of the day is rarely the end of work. The real labor often begins after the door closes, with the slow, meticulous task of translating a conversation into a structured medical note for the electronic health record. It is a universal and exhausting administrative tax on clinical time, one that Oslo-based Noteless was founded in 2023 to automate. By mid-2024, the startup had a simple proposition: turn on a microphone, have a normal consultation, and let an AI generate the note for you [TechFundingNews, Nov 2025].
Now, with a fresh €3.5 million seed round led by Redstone, Noteless is reporting a velocity of adoption that suggests it has struck a nerve. The company says its system has processed more than 3 million patient consultations and is used by around 3,000 clinicians across Norway, Denmark, the UK, Germany, and the Netherlands [TechFundingNews, Nov 2025]. That translates to over 100,000 consultations supported each week [BeBeez International, Nov 2025]. For a tool that sits at the sensitive intersection of patient privacy, clinical accuracy, and physician workflow, those are numbers that demand a closer look.
The Wedge: Real-Time Listening, Not Dictation
The product's wedge is its focus on passive listening rather than active dictation. Unlike traditional speech-to-text tools that require a physician to narrate findings, Noteless is designed to operate in the background. A clinician starts a recording at the beginning of a consultation; the system uses speech recognition and natural language processing to listen to the natural dialogue, then automatically generates a formatted clinical note ready for review and copy-pasting into the EHR [F6S, 2026].
The promise is a direct attack on burnout metrics. The company claims the tool can save clinicians up to two hours per day on documentation, time that can be redirected toward patient care or simply reclaimed from the workday [TechFundingNews, Nov 2025]. This positions Noteless not as a futuristic AI play, but as a pragmatic efficiency tool with a clear, immediate return on investment for its users,healthcare professionals including GPs, specialists, physiotherapists, and psychologists [TechFundingNews, Nov 2025].
Traction and the European Footprint
Growth appears concentrated in Scandinavia but is spreading. The company, which now employs 35 people across Norway, Denmark, and the Netherlands, has built integrations with electronic health record systems used in Norwegian hospitals and the national health portal Helsenorge [BeBeez International, Nov 2025]; [Journal of Medical Internet Research, 2024]. This deep integration into existing clinical workflows is a non-negotiable for adoption, and it is a hurdle many AI tools fail to clear.
The seed funding, which also included participation from Futurum Ventures and Farvatn Venture, will be used to accelerate this expansion across Europe and further develop the AI models [TechFundingNews, Nov 2025]. The backing from Redstone, a fund with a history in European deep tech, suggests investors see a scalable infrastructure layer, not just a point solution.
The Founders and the Regulatory Context
The founding team brings a blend of technical and healthcare domain expertise, a critical mix for navigating the complex European medical device landscape. William Vossgård serves as CEO, with Mikkel Slettebø as CTO. Perhaps most notably, co-founder Sarankan Sivakanesan is a medical doctor, providing an intrinsic clinical lens on product development [Crunchbase]; [Sarankan Sivakanesan - LinkedIn, 2026]. While their prior venture track records aren't detailed in public coverage, the company's rapid execution from founding in late 2023 to a mid-2024 launch and significant scale within a year speaks to operational focus [Female Switch, 2025].
For any clinical documentation tool, the regulatory context is paramount. In Europe, software that creates or informs clinical decisions may fall under the Medical Device Regulation (MDR). Noteless has not publicly detailed its regulatory classification or strategy, a standard point of scrutiny for tools in this category. The company's approach of generating notes for clinician review, rather than making autonomous decisions, likely places it in a lower-risk class, but clarity here will be essential as it moves into larger, more conservative health systems.
Where the Wheels Could Come Off
The clinical AI scribe space is not uncontested. Noteless faces established giants like Nuance Dragon Medical, now part of Microsoft, and well-funded startups like Suki AI. Its current advantages appear to be its European focus, a lightweight deployment model, and early traction in specific national health systems. However, several risks loom on the horizon.
- Accuracy and liability. The core risk for any AI scribe is error. A misheard symptom or an incorrectly inferred diagnosis could have serious consequences. Noteless mitigates this by having the clinician review and approve every note, but the model's underlying accuracy and its performance across diverse accents, medical specialties, and languages will be a constant benchmark.
- Data privacy and sovereignty. Processing millions of sensitive health conversations requires ironclad data governance. Operating across multiple European jurisdictions adds complexity. The company's ability to assure hospitals and clinics of full GDPR and local compliance will be a key purchasing factor.
- The monetization motion. While the company has thousands of users, its business model and average revenue per user are not public. Converting clinicians who may have started on a free or trial tier into paying enterprise contracts is a different motion than seeding adoption. The path to sustainable, high-margin revenue in public healthcare systems is famously long.
The company's most plausible answer to these challenges is its current trajectory: sheer volume of use. Processing over 3 million consultations provides a formidable dataset to continuously improve model accuracy and robustness, potentially creating a data moat that newcomers would struggle to match [TechFundingNews, Nov 2025].
The Next Twelve Months
The immediate roadmap will likely focus on converting its Scandinavian beachhead into durable enterprise contracts while proving expansion in the UK and Germany. Key milestones to watch will be announcements of formal partnerships with large hospital groups or national health services, which would signal a move beyond individual clinician adoption. Given its seed funding and growth rate, a Series A round within the next 12-18 months seems a probable next step.
For the patient population at the heart of this,individuals seeing general practitioners and specialists across Europe,the standard of care today is often a distracted clinician. The physician must split attention between the person in the room and the need to document the encounter accurately, a cognitive load that can diminish the quality of the interaction. Tools like Noteless aim to dissolve that tension, offering the possibility of a consultation where eye contact isn't broken by a keyboard. The bet is that better tools for doctors don't just improve their quality of life; they quietly, fundamentally, improve the quality of care.
Sources
- [TechFundingNews, Nov 2025] Noteless scoops €3.5M to cut doctor paperwork with AI clinical notes | https://techfundingnews.com/noteless-ai-raises-3-5m-to-reduce-doctor-paperwork/
- [BeBeez International, Nov 2025] Noteless article reference |
- [F6S, 2026] Noteless product description | https://www.f6s.com/software/noteless
- [Journal of Medical Internet Research, 2024] Integration reference |
- [Crunchbase] Founder profiles | https://www.crunchbase.com/organization/noteless
- [Sarankan Sivakanesan - LinkedIn, 2026] Medical doctor credential |
- [Female Switch, 2025] Company founding date and launch timeline | https://launch.femaleswitch.com/startup-news-noteless-raises-3-5m-2025-doctors-administrative-challenges-lessons-for-entrepreneurs/